Addressing Challenges of Nonadherence Amongst Adults With Schizophrenia

Sponsored by Johnson & Johnson

In a brand new Psychiatric Instances® Professional Views video sequence sponsored by Johnson & Johnson, Gus Alva, MD, Medical Director of ATP Medical Analysis in Costa Mesa, California, and Desiree Matthews, PMHNP, Proprietor and Medical Director at Totally different Psychological Well being Program, reviewed widespread challenges related to the therapy of schizophrenia, equivalent to therapy nonadherence and relapse. Additionally they reviewed long-acting injectables (LAIs), and particularly once-monthly INVEGA SUSTENNA® (paliperidone palmitate), as choices for adults that may assist handle these challenges.

In keeping with Dr. Alva, schizophrenia requires constant, long-term therapy no matter whether or not signs are current.^1,2 The important thing objectives of therapy embrace delaying time to relapse and bettering general functioning.¹ Delaying relapse is of explicit significance, as relapses could embrace signs equivalent to psychosis, hallucinations, or different disruptive behaviors. Every relapse could cause additional practical deterioration for sufferers, decreased therapy response, and poorer outcomes general.³ Research have even proven that some grownup sufferers could by no means regain their authentic stage of functioning following relapse.¹ “It’s crucial for suppliers to provoke therapy earlier within the illness course to delay danger of relapse,” stated Dr. Alva.⁴

Ideally, therapy must be initiated through the first 5 years following analysis, which is taken into account the “crucial interval” throughout which the illness can progress quickly.⁵ Ms. Matthews elaborated, “Whereas healthcare suppliers (HCPs) can work to deal with the situation at numerous phases, initiating therapy throughout this crucial interval could positively affect short- and long-term outcomes.”⁶

Customary remedies for schizophrenia are oral antipsychotic therapies, which can provide efficacy in as much as 80% of grownup sufferers with schizophrenia.^1,7 Nevertheless, Dr. Alva famous that this efficacy charge could possibly be significantly decrease in the true world. “These outcomes are sometimes hindered by a excessive charge of nonadherence, with roughly half of grownup sufferers not taking their [oral] remedy as prescribed,” he stated.^1,8

Nonadherence is necessary to focus on, shared Ms. Matthews, as a result of it is without doubt one of the foremost predictors of a future relapse. Threat elements for nonadherence can embrace a concern of unwanted side effects, perceptions about therapy, monetary difficulties, schooling stage, stigma, poor social help techniques, and sure psychopathological signs related to schizophrenia, equivalent to delusions and impaired perception.¹ How a therapy is run additionally impacts adherence.^1,9 Since LAIs are administered professionally, suppliers are conscious of when sufferers are nonadherent.¹⁰

LAIs work by repeatedly delivering a constant therapeutic focus over the weeks or months following an injection.¹⁰ They’re administered by a skilled HCP; subsequently, therapy groups have larger perception into when an grownup affected person has missed a dose and might present further help to assist the affected person reinitiate remedy.¹⁰ “I see LAIs as choice for grownup sufferers who’ve a historical past of poor or unsure adherence to orals, particularly those that expertise frequent relapse on account of nonadherence,” stated Dr. Alva.¹¹ “As well as, some grownup sufferers could merely favor the benefit of an injection each month and even much less incessantly moderately than worrying about taking a tablet for his or her schizophrenia every single day.”^1,2

Dr. Alva shared that many suppliers could primarily prescribe oral antipsychotics, they usually contemplate LAIs solely as soon as an grownup affected person is later within the illness course; nevertheless, some medical tips advocate use of LAIs after analysis.⁷ For instance, with an preliminary schizophrenia episode, the Florida Medicaid Program tips advocate administering a second-generation antipsychotic, both as oral-only, or as oral, after which, after establishing efficacy and tolerability, switching to the LAI of the identical antipsychotic.⁷

To allow this transition from oral to LAI, the antipsychotic chosen for therapy would have to be out there as each oral and LAI formulations, stated Dr. Alva.² For instance, the oral formulation of paliperidone can also be out there because the LAI INVEGA SUSTENNA® from Johnson & Johnson, a once-monthly choice for adults with schizophrenia that’s administered by an HCP month-to-month after 2 starter doses.¹² As soon as tolerability has been established at an applicable dose for a minimum of 4 months, grownup sufferers have the choice to transition to the 3-month choice, INVEGA TRINZA® (paliperidone palmitate 3-month), or the 6-month choice, INVEGA HAFYERA® (paliperidone palmitate 6-month).^12-14 “This is the reason we prefer to advocate INVEGA SUSTENNA®—as a result of there’s a chance of shifting to a 3-month choice or a 6-month choice sooner or later,” stated Dr. Alva. Importantly, INVEGA SUSTENNA® “is the one LAI therapy that’s confirmed to be superior to a gaggle of oral antipsychotics in a trial with real-world design components,” he shared.^10,12

Ms. Matthews reviewed particulars of the trial, which was a randomized, open-label, 15-month examine that investigated the efficacy and security of INVEGA SUSTENNA® (n = 226) in comparison with a gaggle of generally prescribed day by day oral antipsychotics (n = 218) for the therapy of schizophrenia.¹⁰ Outcomes from the trial confirmed that “INVEGA SUSTENNA® [was] superior in delaying the time to therapy failure in comparison with a gaggle of seven of essentially the most prescribed day by day orals: aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, and risperidone,” famous Ms. Matthews.¹⁰ “The delay to first therapy failure was statistically vital (imply time to first therapy failure, 416 days for INVEGA SUSTENNA® vs 226 days for orals, P = .011).”¹⁰ As well as, the speed of therapy failure general was significantly decrease with INVEGA SUSTENNA® versus oral remedy (39.8% versus 53.7%, respectively).¹⁰ Remedy failure was outlined as both incarceration, a psychiatric-related hospitalization, suicide, therapy supplementation on account of lack of efficacy, therapy discontinuation on account of lack of efficacy or security, or a rise in psychiatric companies wanted to forestall psychiatric-related hospitalization.¹⁰

“Notably, within the trial, adherence to therapy was significantly increased within the INVEGA SUSTENNA® group, through which 95.2% had a medicine possession ratio (MPR) larger than 80% when assessed utilizing injection information,” stated Ms. Matthews. “That is in distinction to the day by day oral group, through which 24.3% had an MPR larger than 80% when assessed utilizing pharmacy-based prescription refill information.”¹⁰ At month 15, sufferers within the INVEGA SUSTENNA® group had a 30% decrease danger of relapse than these within the day by day oral group.^10,12 Within the Paliperidone Palmitate Analysis in Demonstrating Effectiveness (PRIDE) examine, the 5 most typical hostile occasions within the INVEGA SUSTENNA® group had been injection-site ache (18.6%), insomnia (16.8%), weight improve (11.9%), akathisia (11.1%), and nervousness (10.6%).¹⁰

Concerning security, Dr. Alva famous, “INVEGA SUSTENNA® has a long-term tolerability profile, which makes it choice for suppliers seeking to advocate an LAI to their grownup sufferers.”^10,12 In pivotal, placebo-controlled trials, discontinuation charges on account of hostile occasions had been related between sufferers who acquired INVEGA SUSTENNA® and placebo.¹² The commonest hostile occasions of 5% or larger noticed in these trials had been injection website reactions, somnolence/sedation, dizziness, akathisia, and extrapyramidal dysfunction.¹²

In closing, the specialists emphasised the significance of affected person schooling and shared decision-making throughout therapy choice. Grownup sufferers might not be conscious of those LAIs from Johnson & Johnson as much less frequent dosing choices, or the clinical-related and potential comfort provided by this therapy sort. Ms. Matthews summarized, “By offering long-acting symptom management in every dose and eradicating the day by day reminder of their schizophrenia therapy, LAIs from Johnson & Johnson can permit adults residing with schizophrenia to simplify their therapy routine, keep away from the burden of a day by day schizophrenia tablet, and doubtlessly lead a extra steady day-to-day life with their schizophrenia signs managed.”

INDICATION

INVEGA HAFYERA®, an every-six-month injection, is an atypical antipsychotic indicated for the therapy of schizophrenia in adults after they’ve been adequately handled with:

• A once-a-month paliperidone palmitate prolonged launch injectable suspension (e.g., INVEGA SUSTENNA®) for a minimum of 4 months or
• An every-three-month paliperidone palmitate prolonged launch injectable suspension (e.g., INVEGA TRINZA®) for a minimum of one three-month cycle.

INVEGA TRINZA® is an atypical antipsychotic indicated for the therapy of schizophrenia in sufferers after they’ve been adequately handled with INVEGA SUSTENNA® for a minimum of 4 months.

INVEGA SUSTENNA® is an atypical antipsychotic indicated for the therapy of schizophrenia in adults.

IMPORTANT SAFETY INFORMATION

Contraindications: INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® are contraindicated in sufferers with a recognized hypersensitivity to both paliperidone, risperidone, or to any excipients of their formulation

Cerebrovascular Antagonistic Reactions: Cerebrovascular hostile reactions (e.g., stroke, transient ischemic assaults), together with fatalities, had been reported at the next incidence in aged sufferers with dementia-related psychosis taking risperidone, aripiprazole, and olanzapine in comparison with placebo. No research have been carried out with oral paliperidone, INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® in aged sufferers with dementia. These medicines usually are not accredited for the therapy of sufferers with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS, a doubtlessly deadly symptom complicated, has been reported in affiliation with antipsychotic medicine, together with paliperidone.

Medical manifestations of NMS are hyperpyrexia, muscle rigidity, altered psychological standing together with delirium, and autonomic instability (irregular pulse of blood stress, tachycardia, diaphoresis, and cardiac dysrhythmia). Extra indicators could embrace elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

If NMS is suspected, instantly discontinue INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® and supply symptomatic therapy and monitoring.

QT Prolongation: Paliperidone causes a modest improve within the corrected QT (QTc) interval. Keep away from using medicine that additionally improve QTc interval and in sufferers with danger elements for extended QTc interval. Paliperidone must also be averted in sufferers with congenital lengthy QT syndrome and in sufferers with a historical past of cardiac arrhythmias. Sure circumstances could improve the danger of the prevalence of torsades de pointes and/or sudden loss of life in affiliation with using medicine that extend the QTc interval.

Tardive Dyskinesia (TD): TD, a syndrome consisting of doubtless irreversible, involuntary, dyskinetic actions, could develop in sufferers handled with antipsychotic medicine. Though the prevalence of the syndrome seems to be highest among the many aged, particularly aged ladies, it’s inconceivable to foretell which sufferers will develop the syndrome. Whether or not antipsychotic drug merchandise differ of their potential to trigger tardive dyskinesia is unknown.

The danger of creating TD and the chance that it’ll turn into irreversible seem to extend with the period of therapy and the cumulative dose. The syndrome can develop after comparatively temporary therapy durations, even at low doses. It might additionally happen after discontinuation. TD could remit, partially or fully, if antipsychotic therapy is discontinued. Antipsychotic therapy itself, nevertheless, could suppress (or partially suppress) the indicators and signs of the syndrome, presumably masking the underlying course of. The impact that symptomatic suppression has upon the long-term course of the syndrome is unknown.

If indicators and signs of TD seem in a affected person on INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®, drug discontinuation must be thought-about. Nevertheless, some sufferers could require therapy with INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® regardless of the presence of the syndrome. In sufferers who do require persistent therapy, use the bottom dose and the shortest period of therapy producing a passable medical response. Periodically reassess the necessity for continued therapy.

Metabolic Modifications: Atypical antipsychotic medicine have been related to metabolic modifications which will improve cardiovascular/cerebrovascular danger. These metabolic modifications embrace hyperglycemia, dyslipidemia, and physique weight achieve. Whereas the entire medicine within the class have been proven to supply some metabolic modifications, every drug has its personal particular danger profile.

Hyperglycemia and Diabetes Mellitus: Hyperglycemia and diabetes mellitus, in some instances excessive and related to ketoacidosis, hyperosmolar coma or loss of life, have been reported in sufferers handled with all atypical antipsychotics (APS). Sufferers beginning therapy with APS who’ve or are in danger for diabetes mellitus ought to bear fasting blood glucose testing in the beginning of and through therapy. Sufferers who develop signs of hyperglycemia throughout therapy must also bear fasting blood glucose testing. All sufferers handled with atypical antipsychotics must be monitored for signs of hyperglycemia. Some sufferers require continuation of antidiabetic therapy regardless of discontinuation of the suspect drug.

Dyslipidemia: Undesirable alterations have been noticed in sufferers handled with atypical antipsychotics.

Weight Acquire: Weight achieve has been noticed with atypical antipsychotic use. Medical monitoring of weight is really helpful.

Orthostatic Hypotension and Syncope: INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® could induce orthostatic hypotension in some sufferers on account of its alpha-adrenergic blocking exercise. INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® must be used with warning in sufferers with recognized heart problems, cerebrovascular illness or situations that will predispose sufferers to hypotension (e.g., dehydration, hypovolemia, therapy with antihypertensive medicines). Monitoring must be thought-about in sufferers for whom this can be of concern.

Falls: Somnolence, postural hypotension, motor and sensory instability have been reported with using antipsychotics, together with INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA®, which can result in falls and, consequently, fractures or different fall-related accidents. For sufferers, significantly the aged, with illnesses, situations, or medicines that would exacerbate these results, assess the danger of falls when initiating antipsychotic therapy and recurrently for sufferers on long-term antipsychotic remedy.

Leukopenia, Neutropenia and Agranulocytosis have been reported with antipsychotics, together with INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA®. In sufferers with a historical past of clinically vital low white blood cell depend (WBC)/absolute neutrophil depend (ANC) or drug-induced leukopenia/neutropenia, carry out an entire blood depend incessantly through the first few months of remedy. Think about discontinuing INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® on the first signal of a clinically vital decline in WBC within the absence of different causative elements. Monitor sufferers with clinically vital neutropenia for fever or different signs or indicators of an infection and deal with promptly if such signs or indicators happen. Discontinue INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® in sufferers with extreme neutropenia (absolute neutrophil depend <1000/mm³) and comply with their WBC till restoration.

Hyperprolactinemia: As with different medicine that antagonize dopamine D₂ receptors, INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® elevate prolactin ranges, and the elevation persists throughout persistent administration. Paliperidone has a prolactin-elevating impact much like risperidone, which is related to increased ranges of prolactin elevation than different antipsychotic brokers.

Potential for Cognitive and Motor Impairment: Somnolence, sedation, and dizziness had been reported as hostile reactions in topics handled with INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA®. INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® have the potential to impair judgment, considering, or motor abilities. Sufferers must be cautioned about performing actions that require psychological alertness equivalent to working hazardous equipment, together with motor autos, till they’re fairly sure that INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® don’t adversely have an effect on them.

Seizures: INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® must be used cautiously in sufferers with a historical past of seizures or with situations that doubtlessly decrease seizure threshold. Circumstances that decrease seizure threshold could also be extra prevalent in sufferers 65 years or older.

Administration: For intramuscular injection solely by a healthcare skilled utilizing solely the needles supplied within the INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® kits. Care must be taken to keep away from inadvertent injection right into a blood vessel.

Drug Interactions: Sturdy CYP3A4/P-glycoprotein (P-gp) inducers: Keep away from utilizing a robust inducer of CYP3A4 and/or P-gp (e.g., carbamazepine, rifampin, St John’s Wort) throughout a dosing interval for INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®. If administering a robust inducer is critical, contemplate managing the affected person utilizing paliperidone extended-release tablets.

Being pregnant/Nursing: INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® could trigger extrapyramidal and/or withdrawal signs in neonates with third trimester publicity. Advise sufferers to inform their healthcare skilled in the event that they turn into pregnant or intend to turn into pregnant throughout therapy with INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®. Sufferers must be suggested that there’s a being pregnant registry that screens outcomes in ladies uncovered to INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® throughout being pregnant. INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® can cross into human breast milk. The advantages of breastfeeding must be thought-about together with the mom’s medical want for INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® and any potential hostile impact on the breastfed toddler from INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® or the mom’s underlying situation.

Generally Noticed Antagonistic Reactions for INVEGA HAFYERA®: The commonest hostile reactions (incidence a minimum of 5% within the double-blind section) within the INVEGA HAFYERA® medical trial had been higher respiratory tract an infection, injection website response, weight elevated, headache and parkinsonism.

Generally Noticed Antagonistic Reactions for INVEGA TRINZA®: The commonest hostile reactions (incidence ≥ 5% and occurring a minimum of twice as usually as placebo) had been injection website response, weight elevated, headache, higher respiratory tract an infection, akathisia and parkinsonism.

Generally Noticed Antagonistic Reactions for INVEGA SUSTENNA®: The commonest hostile reactions in medical trials in sufferers with schizophrenia (incidence ≥ 5% and occurring a minimum of twice as usually as placebo) had been injection website reactions, somnolence/sedation, dizziness, akathisia and extrapyramidal dysfunction.

Please click on right here to learn the complete Prescribing Info, together with Boxed WARNING, for INVEGA HAFYERA®, click on right here to learn the complete Prescribing Info, together with Boxed WARNING, for INVEGA TRINZA® and click on right here to learn the complete Prescribing Info, together with Boxed WARNING, for INVEGA SUSTENNA®.

cp-256260v3

References

1. Goldstone LW. Unmet medical wants and different challenges within the therapy of sufferers with schizophrenia. Am J Manag Care. 2020;26(3 Suppl):S48-S54. doi:10.37765/ajmc.2020.43011A
2. Ostuzzi G, Bertolini F, Tedeschi F, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum problems: a community meta-analysis of 92 randomized trials together with 22,645 contributors. World Psychiatry. 2022;21(2):295-307. doi:10.1002/wps.20972
3. Alphs L, et al. Elements related to relapse in schizophrenia regardless of adherence to long-acting injectable remedy. Int Clin Psychopharmacol. 2016;31(4)202-209. doi:10.1097/YIC.0000000000000125
4. Lopena OJ, Alphs LD, Sajatovic M, et al. Earlier use of long-acting injectable paliperidone palmitate versus oral antipsychotics in sufferers with schizophrenia: an built-in patient-level put up hoc evaluation. J Clin Psychiatry. 2023;84(6):23m14788. doi:10.4088/JCP.23m14788
5. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The crucial interval speculation. Br J Psychiatry Suppl. 1998;172(33):53-59.
6. Tandon R, Nasrallah H, Akbarian S, et al. The schizophrenia syndrome, circa 2024: What we all know and the way that informs its nature. Schizophr Res. 2024;264:1-28. doi:10.1016/j.schres.2023.11.015
7. 2019–2020 Florida Greatest Apply Psychotherapeutic Medicine Pointers for Adults. Florida Program for Behavioral Well being Enhancements and Options web site. Revealed January 2020. Accessed April 3, 2024. https://floridabhcenter.org/wp-content/uploads/2021/04/2019-Psychotherapeutic-Medicine-Pointers-for-Adults-with-References_06-04-20.pdf
8. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and danger elements for remedy nonadherence in sufferers with schizophrenia: a complete assessment of latest literature. J Clin Psychiatry. 2002;63(10): 892-909. doi:10.4088/jcp.v63n1007
9. Acosta FJ, Hernández JL, Pereira J, et al. Medicine adherence in schizophrenia. World J Psychiatry. 2012;2(5):74-82. doi:10.5498/wjp.v2.i5.74
10. Alphs L, Benson C, Cheshire-Kinney Ok, et al. Actual-world outcomes of paliperidone palmitate in comparison with day by day oral antipsychotic remedy in schizophrenia: a randomized, open-label, assessment board-blinded 15-month examine. J Clin Psychiatry. 2015;76(5):554-561. doi:10.4088/JCP.14m09584
11. American Psychiatric Affiliation. Apply Guideline for the Remedy of Sufferers With Schizophrenia, third ed. 2021. doi.org/10.1176/appi.books.9780890424841
12. INVEGA SUSTENNA® [Prescribing Information]. Titusville, NJ: Janssen Prescription drugs, Inc.
13. INVEGA TRINZA® [Prescribing Information]. Titusville, NJ: Janssen Prescription drugs, Inc.
14. INVEGA HAFYERA® [Prescribing Information]. Titusville, NJ: Janssen Prescription drugs, Inc.